Login to Your Account

Ventrus Hits Trifecta in Pivotal VEN 307 Trial

By Marie Powers
Staff Writer

Tuesday, May 15, 2012
Shares of Ventrus Biosciences Inc. (NASDAQ:VTUS) gained 14.8 percent Monday, closing at $12.58, after the company reported improvement in three measures of efficacy in a pivotal Phase III study of VEN 307 (diltiazem hydrochloride cream) in anal fissures.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription